

Prof. John O. Prior, PhD MD  
Nuclear Medicine and Molecular Imaging  
Lausanne University Hospital, Switzerland

# Practical radioprotection issues in nuclear medicine at the era of digital PET/ SPECT cameras


*Unil*  
UNIL | Université de Lausanne



Part 1

# Digital SiPM-based PET/CT Technology

# PET: 3 major improvements last 3 decades



# Digital SiPM PET vs. Conventional PMT PET

ORIGINAL RESEARCH

Open Access

Phantom-based image quality assessment of clinical  $^{18}\text{F}$ -FDG protocols in digital PET/CT and comparison to conventional PMT-based PET/CT



Silvana Gnesin<sup>1</sup>, Christine Kieffer<sup>1</sup>, Konstantinos Zeimpekis<sup>2</sup>, Jean-Pierre Papazyan<sup>3</sup>, Renaud Guignard<sup>4</sup>, John O. Prior<sup>5\*</sup>, Francis R. Verdun<sup>1</sup> and Thiago V. M. Lima<sup>1,6</sup>

- 3 digital SiPM+2 convent. PMT PET
- FDG clinical oncologic protocols
- Evaluate trade-off between patient administered activity (*patient dose/signal-to-noise S/N ratio*) vs. acquisition time (*patient comfort*)

- List-mode reconstructions NEMA NU2 phantom (5 kBq/mL in background, 25 kBq/mL in spheres) for 10, 30, 90, 120, 180 & 300 s with 1–10 iterations
- Background coefficient of variation (COV)
- Spheres recovery coefficients (RCs)
- Using Time-activity-product (TAP) = scan time/bed position  $\times$  mass-activity administered (min $\cdot$ MBq/kg)

# Digital SiPM PET vs. Conventional PMT PET

3 different manufacturer:

2 PMT-based PET

3 digital PET

Installed in 2017-2018

*(2 new manufacturer of SiPM  
PET/CT scanners in 2019, not  
included in this study)*

Clinical FDG oncologic PET  
reconstructions protocols

Different matrix and pixel sizes

**Table 1** Systems, acquisition and reconstruction parameters applied in clinical whole-body oncologic  $^{18}\text{F}$ -FDG PET procedures

	Philips Vereos <sup>d</sup>	Siemens Vision <sup>d</sup>	Siemens mCT	GE Discovery-MI <sup>da</sup>	GE Discovery 690
System parameters	<b>dPET</b>	<b>dPET</b>	<b>cPET</b>	<b>dPET</b>	<b>cPET</b>
Axial ring extent (mm)	164	261	221	250	153
Energy window (keV)	450–613	435–585	435–650	425–650	425–650
TOF's resolution (ps)	316	215	540	370	544.3
NEMA System sensitivity (kcps/MBq)	5.6	16.4	9.6	22	7.5
Acquisition parameters					
Acq. Time (min)	1.5	2	2.5	2.5	1.5
Admin. Activity (MBq/kg)	2	2	5	1.5	3.5
Acq. Time (min) × A admin. (TAP in min × MBq/kg)	3	4	12.5	3.75	5.25
Reconstruction parameters					
Reconstruction methods	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF	OSEM 3D TOF + PSF
Iterations and subsets (it,ss)	(3,15)/(2,10)	(4,5)	(3,21)	(3,16)	(3,16)
Filter Gauss FWHM (mm)	0	0	3	6.4	5
Matrix size	144 × 144/ 288 × 288	440 × 440	512 × 512	256 × 256	256 × 256
Pixel size (mm)	4 × 4/2 × 2	1.65 × 1.65	1.59 × 1.59	2.73 × 2.73	2.73 × 2.73
Slice thickness (mm)	4/2	2	5	2.79	3.27


<sup>a</sup>In addition to OSEM, clinic FDG PET protocol for the GE Discovery MI also make use of the Q.Clear reconstruction algorithm (Q-param = 400)

<sup>d</sup>Digital PET systems


# Digital SiPM PET vs. Conventional PMT PET

→ RC comparable between digital and PMT-based PET

→ EARL (2017) surpassed by most recent PET/CT systems



# Digital SiPM PET vs. Conventional PMT PET




→ Compared to PMT-based PET, digital systems have comparable image quality for lower TAP (–40% to –70%)


# Digital SiPM PET vs. Conventional PMT PET

## Conclusions

- Image quality was comparable with a **TAP reduction of >40%** in digital PET
- Leads to significant reduction in mass activity or time with direct benefit for **patient dose exposure** and **comfort**




Discovery-MI Q-400




Q.Clear (Q-400); M256

Vereos M144




3i×15s; M144; G=0mm

Discovery-MI




3i×16s; M256; G=6.4mm

Vereos M288



2i×10s; M288; G=0mm

Bq/mL



*Different matrix  
and pixel sizes!*

*No spheres <10mm*







*2<sup>nd</sup> Worldwide installation in June 2018, N>5000 patients as of today*

Prof. Dr. Dr. John Prior  
Lausanne University Hospital

# Initial Clinical Experience Digital SiPM-based PET/CT



# First patient in Lausanne (June 2018)



PET

CT

PET/CT fusion


PET

CT

PET/CT fusion



# Today's Challenge in Oncologic Imaging



Identify all lesions is key  
to defining right therapy


Local?

Lymph nodes?

Metastases?


Poor spatial resolution  
and sensitivity negatively  
affects lesion detectability  
and staging

# 55-y uveal melanoma patient




Extensive liver  
metastases

# 55-y uveal melanoma patient



# Detectability of small structures in FDG PET/CT


Visual observations of the pituitary gland



**Non-Si-PM PET/CT**

Gauss filter FWHM = 5mm

Voxel size : 2.74×2.74×3.27 mm




**SiPM PET/CT**

No gaussian Filter

Voxel size : 1.65×1.65×2mm

→ **Reduced partial volume effect**


# Increased signal recovery from small structures



- Comparison of physiological uptake of a small structure — **the pituitary gland (PG)** — on dPET and cPET
- Modified NEMA/IEC phantom study with  $\varnothing 20$ -, 10-, 7-, 5-, 3- and 2-mm hot spheres
- 3x and 5x higher sphere activity than background concentration
- Acquisition times 1, 2, 3, 5 min
- N=10 patients each in dPET & cPET with measured SUV<sub>max</sub>, SUV<sub>mean</sub>, and PG volume

# Increased signal recovery from small structures

5x higher activity in spheres vs. background



Spheres  $\varnothing$ 20, 10, 7, 5, 3, and 2 mm

→ Superior signal recovery and small region detectability with dPET

# Increased signal recovery from small structures

3x higher activity in spheres vs. background



<u>3x</u>	<u>1 min</u>		<u>2 min</u>		<u>3min</u>		<u>5min</u>	
Sphere	cPET	dPET	cPET	dPET	cPET	dPET	cPET	dPET
20 mm	7.62	7.42	10.33	10.11	13.18	11.95	16.9	15.76
10 mm	2.82	3.68	3.13	5.04	4.05	6.36	5.4	8.15
7 mm	1.2	1.49	1.15	2.7	1.74	3.09	1.97	3.03

5x higher activity in spheres vs. background

<u>5x</u>	<u>1 min</u>		<u>2 min</u>		<u>3min</u>		<u>5min</u>	
Sphere	cPET	dPET	cPET	dPET	cPET	dPET	cPET	dPET
20 mm	17.55	16.02	23.74	22.25	28.38	27.41	35.67	35.5
10 mm	8.63	10.9	12.09	15.08	12.85	18.2	15.77	23.74
7 mm	5.03	3.33	4.81	5.65	6.04	8.49	6.69	12.34
5 mm	-0.02	4.05	0.5	3.55	0.35	4.37	0.56	4.68

Signal difference to noise ratio: SDNR >3 for detection  
(according to EARL 2017)

# Increased signal recovery from small structures



Conclusions:

→ Awareness of “higher” SUV of normal pituitary FDG uptake is important to avoid potential pitfalls in interpretation

→ Of importance in oncologic patients under immunotherapy, who are at increased risk to develop hypophysitis (PG inflammation)

# Lesion Detectability with Digital PET

N=100 oncological patients  
Comparison dPET vs. cPET  
Improved image quality in 54 patients

dPET detected more lesions  
in 22 patients, all <10mm  
dPET changed staging in  
32% of these 22 patients

European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:1383–1390  
<https://doi.org/10.1007/s00259-019-4260-z>

## ORIGINAL ARTICLE



### Comparison of image quality and lesion detection between digital and analog PET/CT

Diego Alfonso López-Mora<sup>1</sup> · Albert Flotats<sup>1</sup> · Francisco Fuentes-Ocampo<sup>1</sup> · Valle Camacho<sup>1</sup> · Alejandro Fernández<sup>1</sup> · Agustí Ruiz<sup>2</sup> · Joan Duch<sup>1</sup> · Marina Sizova<sup>1</sup> · Anna Domènech<sup>1</sup> · Montserrat Estorch<sup>1</sup> · Ignasi Carrió<sup>1</sup>

Received: 14 November 2018 / Accepted: 2 January 2019 / Published online: 10 January 2019  
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

#### Abstract

**Objective** The purpose of this study was to compare image quality and lesion detection capability between a digital and an analog PET/CT system in oncological patients.

**Materials and methods** One hundred oncological patients (62 men, 38 women; mean age of 65 ± 12 years) were prospectively included from January–June 2018. All patients, who accepted to be scanned by two systems, consecutively underwent a single day, dual imaging protocol (digital and analog PET/CT). Three nuclear medicine physicians evaluated image quality using a 4-point scale (−1, poor; 0, fair; 1, good; 2, excellent) and detection capability by counting the number of lesions with increased radiotracer uptake. Differences were considered significant for a  $p$  value < 0.05.

**Results** Improved image quality in the digital over the analog system was observed in 54% of the patients ( $p = 0.05$ , 95% CI: 44.2–63.5). The percentage of interrater concordance in lesion detection capability between the digital and analog systems was 97%, with an interrater measure agreement of  $\kappa = 0.901$  ( $p < 0.0001$ ). Although there was no significant difference in the total number of lesions detected by the two systems (digital:  $5.03 \pm 10.6$  vs. analog:  $4.53 \pm 10.29$ ;  $p = 0.7$ ), the digital system detected more lesions in 22 of 83 of PET+ patients (26.5%) ( $p = 0.05$ , 95% CI: 17.9–36.7). In these 22 patients, all lesions detected by the digital PET/CT (and not by the analog PET/CT) were < 10 mm.

**Conclusion** Digital PET/CT offers improved image quality and lesion detection capability over the analog PET/CT in oncological patients, and even better for sub-centimeter lesions.

**Keywords** Digital PET/CT · Analog PET/CT · Lesion detection capability · Image quality

# CHUV: HF Pulsatile Flow Ventilation Apnea PET/CT

## BRIEF COMMUNICATIONS

### Reduction of Respiratory Motion During PET/CT by Pulsatile-Flow Ventilation: A First Clinical Evaluation

John O. Prior<sup>1</sup>\*, Nicolas Pègret<sup>2,3</sup>, Anastasia Pomoni<sup>1</sup>, Martin Pappou<sup>1</sup>, Michele Zeverino<sup>1</sup>, Bastien Belmondo<sup>1</sup>, Alban Louis<sup>1</sup>, Mahmut Otashin<sup>1</sup>, Monique Vienne<sup>1</sup>, and Jean Bourhis<sup>2</sup>

<sup>1</sup>Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland; <sup>2</sup>Department of Radiation Oncology, Lausanne University Hospital, Lausanne, Switzerland; <sup>3</sup>Department of Medical Physics, Lausanne University Hospital, Lausanne, Switzerland; <sup>4</sup>Department of Physiotherapy, Lausanne University Hospital, Lausanne, Switzerland; <sup>5</sup>Department of Pneumology, Lausanne University Hospital, Lausanne, Switzerland; and <sup>6</sup>BIRD Institute of Pulmonary Care, Villeneuve-Loubet, France

Respiratory motion negatively affects PET/CT image quality and quantitation. A novel Pulsatile-Flow Ventilation (PFV) system reducing respiratory motion was applied in spontaneously breathing patients to induce subtidal apnea during PET/CT. **Methods:** Four patients (aged 65 ± 14 y) underwent PET/CT for pulmonary nodule staging (mean, 11 ± 7 mm; range, 5–18 mm) at 63 ± 3 min after <sup>18</sup>F-FDG injection and then at 47 ± 7 min afterward, during PFV-induced apnea (both imaging lasting 3.5 min). Anterior-posterior thoracic amplitude, SUV<sub>max</sub>, and SUV<sub>mean</sub> (SUV<sub>mean</sub> in a 1-cm-diameter sphere) were compared. **Results:** PFV/CT induced thoracic amplitude (80%), increased mean lesion SUV<sub>max</sub> (29%), and SUV<sub>mean</sub> (11%), decreased lung background SUV<sub>max</sub> (25%), improved lesion detectability, and increased SUV<sub>max</sub> lesion-to-background ratio (34%). On linear regressions, SUV<sub>max</sub> and SUV<sub>mean</sub> significantly improved by 25% and 23%, respectively,  $P < 0.02$ . **Conclusion:** PFV-induced apnea reduces thoracic organ motion and increases lesion SUV, detectability, and delineation, thus potentially affecting patient management by improving diagnosis, prognostication, monitoring, and external-radiation therapy planning.

**Key Words:** PET/CT; high-frequency percussive ventilation; PFV; respiratory motion; Pulsatile-Flow Ventilation

J Nucl Med 2016; 57:416–419  
DOI: 10.2967/jnumed.115.163086

PET/CT has become a major oncologic imaging modality for diagnosis, prognostication, therapy monitoring, and radiation therapy planning (1). Respiratory motion has significant negative effects on image quality, on the accuracy with which PET quantifies lesion activity, on fusion accuracy, and on delineation of lesion volume (2). Several advanced PET/CT respiration-gating techniques have been developed to pulsate thoracic organ motion (3). All have intrinsic limitations, such as longer PET acquisitions, mixing of several lesion positions in a single bin, and difficulty

with irregular breathing patterns. In addition, not only PET but also CT should be gated to avoid introducing supplementary attenuation correction and quantification errors (2). Today, these techniques are not universally applied and no consensus exists as to the best method to compensate for respiratory motion.

HFV (high-frequency percussive ventilation; OxyCan GmbH) was first designed to promote airway clearance through a percussive flow of air. On the basis of this hygienic effect, HFV was then developed in intensive care units, with percussive airflow favoring evacuation of airway debris secondary to intubation injury (5). The physical principle is to deliver high-frequency ventilation (>400/min) in low ventilation cycles (10–50 cycles/min). Clinical experience demonstrated improved lung compliance, oxygenation, and ventilation compared with conventional ventilation in intensive care. These benefits extended the indication as a salvage modality for acute respiratory distress syndrome, with clinical evidence supported by smaller trials. Successive subtidal breathing with added high-frequency oscillations to both the inflation phase and the exhalation phase facilitates oxygen diffusion and carbon dioxide removal. We refined this technique to obtain apneic respiratory motion stabilization at full inspiration for medical imaging and radiation therapy (4). We achieved apnea lasting 8–16 min, allowing radiation therapy in non-intubated patients (6).

We aimed at establishing Pulsatile-Flow Ventilation (The BIRD Institute of Pulmonary Care, Villeneuve-Loubet, France) PET/CT (PFV) to suppress respiratory motion and quantify lesion detectability and quantification.

#### MATERIALS AND METHODS


##### Patient Population

Four patients (mean age: 50.65 ± 14 y) with a pulmonary insured lesion (mean size, 11 ± 7 mm; range, 5–18 mm) deemed suitable for radiation therapy were assessed in this research protocol, which was authorized by the State of Valais Ethics Committee on Human Research. All patients signed an informed consent form. We had originally enrolled 5 patients (between November 2014 and April 2015), but 1 patient refused to undergo PFV PET/CT. The clinical characteristics of the 4 assessed patients are presented in Table 1.



##### <sup>18</sup>F-FDG PET/CT Acquisition

Images were acquired on a time-of-flight PET/CT scanner (Discovery 690; GE Healthcare) with scatter and prior-gated thoracic recovery corrections, 60 min after injection of <sup>18</sup>F-FDG (3.5 MBq/kg) and after the patients had fasted for at least 6 h (PET: 2 min/bed position, 47 slices, 256 × 256 matrix, ordered subsets expectation

## A Free-breathing




## B Free-breathing




Received Jul. 5, 2015; revision accepted Nov. 16, 2015.  
For correspondence and reprint requests, please contact: Jean Bourhis, Lausanne University Hospital, Bâton 46, 1011 Lausanne, Switzerland.  
E-mail: jean.bourhis@chuv.ch.  
\*Contributed equally to this work.  
Published online Dec. 2, 2015.  
COPYRIGHT © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.


# Free-breathing vs. “Breath-hold” PET



# Free-breathing vs. “Breath-hold” PET



# Importance for lung cancer screening?




N=6 patients with lung nodule ( $15 \pm 8$  mm)

100%, 50% and 10% of activity decimated reconstructions, 90-s/bed position


→  $SUV_{mean}$  decreased by 10% in 0.2 MBq/kg with stable signal-to-background ratio

# Ga-68-PSMA-11 PET/CT Staging Primary PCa





62-y Men with  
primary PCa



# Ga-68-PSMA PET/CT Staging Primary PCa



# Ultrafast PET (<5-min)




13-min PET (CBM, 1.5-min/bed equivalent)



5-min PET

→ *Identical SUV measurements*

# Ultrafast whole-body PET (<5-min)



15-min PET (CBM, 1.5-min/bed equivalent)

5-min PET

→ *Identical SUV measurements*

# Less dose exposition

3.5 MBq / kg



Patient  
Dose



2 MBq / kg

–42% Reduction  
Activity & Dose



Technologists and  
Staff dose

Public (returning  
@work or @home)




Automated injectors:  
– More patient with same vial  
– Less manipulation of activity



# Brain PET



cPET



dPET





# Rubidium-82 Cardiac-PET



5 MBq/kg Rb-82 (86 kg) 430 MBq  
6-Min Stress + Rest acquisitions

# Reducing Rb-82 activity in cardiac PET/CT




Halved  $^{82}\text{Rb}$ -Injected Activity Using High-Resolution, High-Sensitivity and 214-ps SiPM PET/CT in Comparison to a 500-ps System with Standard Activity

Mario Jreige, Christel Kamani, Gilles Allenbach, Martin Pappon,  
Patrick Genoud, Silvano Gnesin, Marie Nicod-Lalonde, Niklaus G. Schaefer,  
John O. Prior


NUCLEAR MEDICINE DEPARTMENT, LAUSANNE UNIVERSITY HOSPITAL (CHUV),  
LAUSANNE, SWITZERLAND

- 10MBq/kg with 500-ps cPET
- 5 MBq/kg with 214-ps dPET
- N=12 individuals with normal MBF in each group

# Comparison 10 MBq/kg vs. 5 MBq/kg




500-ps TOF cPET



214-ps TOF dPET

# Results



SNMMI 2019 Annual Meeting  
ANAHEIM, CALIFORNIA  
JUNE 22-25, 2019

< SNMMI Annual Meeting

**SS13: Cardiovascular YIA Symposium**

🕒 12:30 PM - 2:00 PM, Sun, Jun 23, 2019


No. 101

01:00 PM



**Halved<sup>82</sup>Rb-Injected Activity Using High-Resolution, High-Sensitivity and 214-ps SiPM - PET/CT in Comparison to a 500-ps System with Standard Activity.**

Mario Jreige, Lausanne University Hospital


# Y-90 TOF PET after SIRT




20-min PET  
high-sensitivity




# Total-Body PET Axial Length vs. Cost



Base Price PET 20-cm → 2 MCHF




# Total-body PET (Explorer, 2m)



2 m de long

560'000 cristaux


PET en 30-40 seconds ou 1/40 l'activité habituelle



0 min 0 sec

# Total-body PET (Explorer, 2m)


$^{68}\text{Ga}$ -PSMA Imaging, with different scan time



82kg, 3.35mCi  $^{68}\text{Ga}$ -PSMA, imaged for 10 minutes(left) at 80min post injection.

Image Courtesy of Sun Yat-sen Univ.'s Cancer Center

# High sensitivity (total body) imaging




Comparable  
image quality  
at 9 hours as  
today's clinical  
system at 1  
hour


# Total-Body PET/CT Captures Full Picture of Systemic Inflammatory Arthritis

uEXPLORER total-body  $^{18}\text{F}$ -FDG PET/CT scans in Arthritis


Psoriatic Arthritis



Rheumatoid Arthritis



Osteoarthritis



Low  
radiation  
dose:  
20-min scan  
**75 MBq**  
**F-18-FDG**  
**→ 1.4 mSv**

# Total-body PET (Explorer, 2m)

## Benefits:

Better

Faster

Later after  
injection

Lower dose

Total-body  
dynamic

- Major increase in dynamic range

can image for 5 more half lives

- $^{11}\text{C}$   
> 3 hours

- $^{18}\text{F}$   
> 16 hours

- $^{89}\text{Zr}$   
> 30 days



Conventional PET




EXPLORER

# Long axial FOV PET



1.06-meter



10-min  
PET



PET MIP

1 bed position / 10 min per bed



Axial



Coronal

→190 MBq

4-min  
PET



PET MIP

1 bed position / 4 min per bed



Axial



Coronal

→76 MBq

1-min  
PET



PET MIP

1 bed position / 1 min per bed



Axial



Coronal

→19 MBq

15-s  
PET




PET MIP

1 bed position / 15 sec per bed




Axial



Coronal


→5 MBq

# PET: 3 major improvements last 3 decades



# 10-ps TOF PET: Advantages

Next technology?



- 1.5-mm resolution along LOR
- Tomography-less real-time reconstructions (“Anger-camera”-like)
- Total-body with sparse detectors
- Increase PET sensitivity ( $>16$ )
- Reduction in activity per dose, reduced price
- Better quantification @low count  $\rightarrow$  ultra low-dose screening (oncology, psychiatric & infectious diseases)

*P. Lecoq, C. Morel, J. Prior, 2018*

# Clinical improvements

Better resolution (tumor microenvironment)

Better sensitivity

- Less activity

- Image longer (C-11 4h, F-18 20h, Zr-89 30d)

- Image faster (respiratory/cardiac/GI movements)

- High temporal resolution

- 200-fold reduction ( $0.03 \text{ mSv} = 2.5\text{d natural irradiation}$ )

- Image more often

# Novel clinical applications (1)

Precise quantification of low-activity metabolism, such as apoptosis (programmed cell death) in myocardial infarct, chronic heart failure, stroke or neurodegeneration (Alzheimer or Parkinson's disease)


→ may help to develop new drugs or better follow and treat disease activity

# Novel clinical applications (2)

Lung cancer screening (with CT: now 96% false positive rate) → better with ultra-low-dose PET

Non-fatal disease: tuberculosis (India, China, South Africa,  $10 \cdot 10^6$  new cases/ $1.8 \cdot 10^6$  death in 2015), HIV, also (schizophrenia, mental disorders)

SARS-CoV-2...




# Novel clinical applications (3)

Radiation dose equivalent to a few days–weeks of natural radioactivity

Advantages for pediatric NM, but also for fetal growth and placental pathology (obstructive uropathy, brain development, hypoxic insult, abnormal fetal motor behavior and epilepsy) → benefit to percutaneous or fetal surgery, which has entered the clinical arena

# 10-ps TOF-PET improvement simulation



Non-TOF  
FBP



Non-TOF  
OSEM



10ps TOF  
FBP



10ps TOF  
OSEM

Therefore...

# Creation of the 10-ps TOF PET Challenge

<http://the10ps-challenge.org>

# The 10ps challenge: a step toward reconstructionless TOF-PET


## The 10ps challenge:

- a spur on the development of fast timing
- an opportunity to get together
- an incentive to raise funding
- a way to shed light on nuclear instrumentation for medical imaging

One unique challenge launched for 5 to 10 years and operated by an international organisation with rules issued by the community based on the measurement of CTR combined to sensitivity

## Several milestones and prizes:

- 3 years after the launch of the challenge: 1M€ expected for the Flash Gordon prizes for the realisation of 3 important milestones
- until the end of the challenge: 1M€ expected for the Leonard McCoy prize for the first team meeting successfully the specifications of the challenge



Non-TOF  
FBP



Non-TOF  
OSEM



10ps TOF  
FBP



10ps TOF

# <http://the10ps-challenge.org>

## Endorsement



EUROPEAN INSTITUTE  
FOR BIOMEDICAL  
IMAGING RESEARCH



IEEE NPSS NMISC




PETsys  
Electronics

Worldwide:  
42 PET Scientists  
and Physicians



As of January 2021




## Part 2

# Hybrid whole-body CZT gamma-camera

# Hybrid whole-body CZT gamma-camera



(NM/CT 670 CZT)  
NM/CT 870 CZT





VERITON-CT


Different collimation systems

# CZT detectors for nuclear imaging

1. **Direct** detection enabling **high detection efficiency**
2. **Small pixelated** detectors (2.46 mm, compact design)
3. **High energy resolution** (2 x higher than NaI(Tl))
4. **Currently a maximal energy** in the range  $\sim 200$  keV for the detected photons



# 360° CZT VERITON™ system



12 detectors  
8 CZT modules per  
detector




**Swiveling** detectors in  
close **proximity** to the  
patient

**Direct photon conversion**


## Full 360° FOV Scan

Projections acquired  
from the entire FOV



## Focused 360°FOV Scan

80 to 100% of the  
projections acquired  
directly from a ROI



# Myocardial perfusion SPECT

Decreased Activity & Time  
Cardiac dynamic SPECT possibility (software exists)

## Patient 01

Sex F

160 cm / 52 kg


Stress:

103 MBq – 10 min

Rest:

290 MBq – 5 min

**Anterior  
infarction**



Stress SA

Rest SA

Stress VLA

Rest VLA

Stress HLA

Rest HLA

## Patient 02

Sex M

173 cm / 85 kg


Stress:

150 MBq – 10 min

Rest:

461 MBq – 5 min

**Apical  
ischemia**



Stress SA

Rest SA

Stress VLA

Rest VLA


Stress HLA

Rest HLA

# Organ and whole-body imaging




# Hybrid whole-body CZT imaging



# Dedicated brain perfusion SPECT



**A**



**B**


Anger  
SPECT  
30-min

Brain-CZT  
SPECT  
15-min

Anger  
SPECT

Brain-CZT  
SPECT


CT



Improved image quality, potential to decrease activity or time

Bordonne M et al, J Neurorad 2019

# Hybrid whole-body CZT imaging



European Journal of Nuclear Medicine and Molecular Imaging  
<https://doi.org/10.1007/s00259-019-04525-y>

IMAGE OF THE MONTH

Augmented planar bone scintigraphy obtained from a whole-body SPECT recording of less than 20 min with a high-sensitivity 360° CZT camera

Saifedine Melki<sup>1</sup> · Mohammad Bilal Chawki<sup>1,2</sup> · Pierre-Yves Marie<sup>1,3</sup> · Laetitia Imbert<sup>1,3,4</sup> · Antoine Verger<sup>1,3,4</sup>

Received: 12 June 2019 / Accepted: 4 September 2019  
 © Springer-Verlag GmbH Germany, part of Springer Nature 2019

Low-dose CT (<2 mSv)  
 (6 to 7) x (3-min bed position)

Melki S et al. EJNMMI 2019

Unil  
 UNIL | Université de Lausanne

CZT

# **SPECT/CT with GE 670 CZT**

## A Swiss experience

---

*Courtesy of Renaud Guignard, MD, La Tour Hospital, Geneva, Switzerland*

---

# Cardiac MPI with hybrid whole-body, CZT-based camera

GE 670 CZT installed in June 2018, first 2 years: >800 MPI studies

Prone position (>75%), systematic gated-SPECT and (stress) CTAC

2 protocols:

- **1-day stress-rest** (90% of patients) with stress first and rest only performed if abnormal stress results
- **2-day stress-rest** for obese patients in screening setting (BMI > 35 kg/m<sup>2</sup>)

Radiopharmaceutical: <sup>99m</sup>Tc-tetrofosmin

Pharmaceutical stress agent: regadenoson 400µg/5mL

Average total counts: 7 million counts (stress) / 25 million counts (rest)

### Patient history:

- 68 year-old man; 123 kg (BMI 40.2)
- effort dyspnea; no history of CAD
- Negative pharmacologic stress test

### Technical parameters:

- 1200 MBq  $^{99m}\text{Tc}$ -tetrofosmin (CT-scan DLP: 21 mGy.cm<sup>-1</sup>)
- Supine position; 2 day-protocol



### Stress-rest myocardial perfusion images (NAC)

#### QGS stress results

LVEF: 60%  
EDV: 142 mL  
ESV: 57 mL

#### QGS rest results

LVEF: 65%  
EDV: 135 mL  
ESV: 48 mL



7.5-min

7.5-min

NAC

Decreased Acquisition  
Time by 30–40%

### SPECT-CT acquisitions (real time $\approx$ 10 minutes)

30 x 2 projections; 15 seconds/bed  
(L-configuration; 64x64; zoom 1.3; orbit:180°)

### Reconstruction parameters:

OSEM 2it10sub; BW filter 0.4/10; +/- AC corrections

### Patient history:

- 68 year-old man; 123 kg (BMI 40.2)
- effort dyspnea; no history of CAD
- Negative pharmacologic stress test

### Technical parameters:

- 1200 MBq  $^{99m}\text{Tc}$ -tetrofosmin (CT-scan DLP: 21 mGy.cm<sup>-1</sup>)
- Supine position; 2 day-protocol


### Stress-rest myocardial perfusion images (AC)

#### QGS stress results

LVEF: 60%  
EDV: 142 mL  
ESV: 57 mL

#### QGS rest results

LVEF: 65%  
EDV: 135 mL  
ESV: 48 mL



7.5-min

7.5-min

### CONCLUSION

- No significant perfusion defect
- Inferior wall attenuation

### SPECT-CT acquisitions (real time $\approx$ 10 minutes)

30 x 2 projections; 15 secondes/bed  
(L-configuration; 64x64; zoom 1.3; orbit:180°)

#### Reconstruction parameters:

OSEM 2it10sub; BW filter 0.4/10; +/- AC corrections

# Lung scan

No pulmonary embolism


## Technical parameters:

- 80y old woman; 106 kg; BMI 41.1; supine position
- V: Technegas/ Q: 200 MBq  $^{99m}\text{Tc}$ -MAA (CT-scan DLP: 92 mGy.cm<sup>-1</sup>)

VENTILATION (coronal AC view)




PERFUSION (coronal AC view)



# WB bone scan + 3FOV SPECT («PET-like») for oncological purpose

## Technical parameters:



- 73y old man; 75 kg; BMI 29.3; supine position
- 781 MBq  $^{99m}\text{Tc}$ -nanocolloïd (CT-scan DLP: 620 mGy.cm<sup>-1</sup>)
- Injection-acquisition time: 3 hours



# DATscan (+analysis)



## Technical parameters:

- 82y old man; 77 kg; BMI 23.8; supine position
- 191 MBq  $^{123}\text{I}$ -loflupane
- Injection-acquisition time: 3 hours







# Unique dual-isotope simultaneous acquisition (CZT-improved energy resolution)


Cortical Region	Patient	Normal	Diff.	Z-Score
Prefrontal Lateral R	0.87	0.96	-0.09	-4.49
Prefrontal Lateral L	0.85	0.95	-0.11	-5.76
Prefrontal Medial R	0.84	0.95	-0.11	-3.53
Prefrontal Medial L	0.87	0.95	-0.07	-2.18
Sensorimotor R	0.98	0.94	0.03	1.26
Sensorimotor L	0.94	0.95	-0.00	-0.05
Anterior Cingulate R	0.85	0.93	-0.08	-1.53
Anterior Cingulate L	0.82	0.94	-0.12	-2.36
Posterior Cingulate R	1.01	0.99	0.02	0.54
Posterior Cingulate L	0.99	0.98	0.00	0.04
Precuneus R	1.13	1.00	0.13	3.99
Precuneus L	1.13	0.98	0.15	3.86
Parietal Superior R	0.99	0.91	0.08	1.92
Parietal Superior L	0.88	0.87	0.01	0.31
Parietal Inferior R	0.98	0.87	0.01	0.50
Parietal Inferior L	0.89	0.95	-0.06	-2.38
Occipital Lateral R	1.07	0.92	0.16	6.15
Occipital Lateral L	1.04	0.92	0.12	5.67
Primary Visual R	1.14	1.00	0.14	2.77
Primary Visual L	1.03	1.01	0.02	0.68
Temporal Lateral R	0.77	0.93	-0.16	-6.75
Temporal Lateral L	0.85	0.92	-0.07	-3.14
Temporal Medial R	0.75	0.85	-0.10	-2.85
Temporal Medial L	0.77	0.86	-0.09	-2.44
Cerebellum	0.95	0.93	0.02	0.69
Pons	0.83	0.87	-0.04	-0.70



Ceretec™ & DATscan™




# Comparison of whole-body vs. cardiac CZT



- Acquisitions in phantom and N=10 patients
- Spatial resolution was identical
- Count sensitivity was 2x smaller with whole-body CZT with lower sharpness index and contrast-to-noise ratio
- Wall thickness and LV volumes were identical

# High-speed scanning of $^{123}\text{I}$ -mIBG planar images using a whole-body CZT camera

- N=36 patients
- List-mode acquisition
- Acquisition duration of 300-, 200-, 100- and 50-s
- → acquisition time can be reduced by 5x




# Summary: Digital PET/SPECT Cameras

## PET:

- Improved detectability & quantification in smaller structures, clinical impact++
- **Lower injected activity AND scan duration**
- Total-body PET: new horizons in systems biology imaging, high \$\$\$
- 10-ps TOF PET Challenge: opportunity for even higher sensitivity (202X?)

## SPECT:

- Increased energy resolution (2x better)
- Increased resolution as compared to conventional NaI camera
- Clinical impact less clear
- **Lower scan duration OR less often decrease injected activity**
- Only low-medium energy (no  $^{131}\text{I}$ , not optimal for  $^{111}\text{In}$ ,  $^{177}\text{Lu}$ )
- Electronic collimation (202X?)



Lausanne,  
Switzerland

*Thank you for your attention!*

<http://the10ps-challenge.org>